Furthermore, in colon cancer patients, MMP-2 expression had prognostic value for patient survival when PRL-3 was highly expressed (p = 0.023; Fig. 6d, right panel), but not when PRL-3 was expressed at lower levels (p = 0.851; Fig. 6d, left panel), suggesting that the value of MMP-2 as a prognostic marker might be associated with PRL-3-driven mTOR hyperactivity. This evidence concerns the gene MTOR and malignant colon neoplasm.